{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DOXIL&page=13", "query": { "intervention": "DOXIL", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 1379, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DOXIL&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DOXIL&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T05:23:29.406Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02116530", "title": "Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)", "type": "DRUG" }, { "name": "Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 401, "start_date": "2014-08-20", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 177, "location_summary": "Anchorage, Alaska • Burbank, California • Dublin, California + 109 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02116530" }, { "nct_id": "NCT04824092", "title": "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tafasitamab placebo", "type": "DRUG" }, { "name": "Lenalidomide placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 899, "start_date": "2021-05-11", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 47, "location_summary": "Daphne, Alabama • Anaheim, California • Clovis, California + 44 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04824092" }, { "nct_id": "NCT00632827", "title": "Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride Liposome Injection", "type": "DRUG" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Denileukin diftitox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2008-07-01", "completion_date": "2016-06-23", "has_results": true, "last_update_posted_date": "2020-04-27", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00632827" }, { "nct_id": "NCT00116961", "title": "Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2005-06", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2012-02-07", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116961" }, { "nct_id": "NCT00671658", "title": "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide (CTX)", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Pegylated asparaginase", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 220, "start_date": "2002-11", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671658" }, { "nct_id": "NCT00006034", "title": "Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Intracel", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-05-15", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 1, "location_summary": "Frederick, Maryland", "locations": [ { "city": "Frederick", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006034" }, { "nct_id": "NCT00165087", "title": "Treatment of Childhood Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "asparaginase (E. Coli)", "type": "DRUG" }, { "name": "asparaginase (Erwina)", "type": "DRUG" }, { "name": "dexrazoxane", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "cranial radiation (once daily fractionation)", "type": "PROCEDURE" }, { "name": "cranial radiation (twice-daily fractionation)", "type": "PROCEDURE" }, { "name": "Intrathecal chemotherapy without radiation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 491, "start_date": "1996-01", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2007-12-28", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 6, "location_summary": "New Orleans, Louisiana • Lewiston, Maine • Boston, Massachusetts + 2 more", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Lewiston", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00165087" }, { "nct_id": "NCT05020860", "title": "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Neoplasm", "Breast Cancer Female", "Breast Cancer Invasive", "Breast Cancer Stage II", "Breast Cancer Stage III", "Triple Negative Breast Cancer", "Hormone Receptor-positive Breast Cancer", "HER2-positive Breast Cancer", "Triple Negative Breast Neoplasms", "Estrogen Receptor-positive Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pertuzumab/Trastuzumab/Hyaluronidase-zzxf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2023-04-18", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020860" }, { "nct_id": "NCT00441376", "title": "A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Liver Neoplasms" ], "interventions": [ { "name": "ThermoDox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2007-02", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2019-02-07", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 1, "location_summary": "Manhasset, New York", "locations": [ { "city": "Manhasset", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00441376" }, { "nct_id": "NCT01027910", "title": "PCI-24781 in Combination With Doxorubicin to Treat Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "PCI-24781", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "GCSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-02", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2025-07-24", "last_synced_at": "2026-10-20T05:23:29.406Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01027910" } ] }